Drug Trial Radar · NCT07307495
Effect of Postoperative Analgesia of Oliceridine Fumarate for Gastrointestinal Function Recovery in Patients Undergoing Lumbar Spine Surgery
Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
428
Planned (sponsor's estimate)
Start
Mar 30, 2026
Primary completion
Jul 1, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Xijing HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 29, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Osemitidine fumarate is a novel G protein-biased ligand μ-opioid receptor agonist. Previous studies have confirmed its potent analgesic effects and safety: compared with morphine, it reduces respiratory depression and gastrointestinal dysfunction. This study aims to evaluate the effects of osemitidine on postoperative gastrointestinal function recovery and pain in patients undergoing lumbar spine surgery through a multicenter, double-blind, randomized controlled trial.
Conditions
- Oliceridine Fumarate
Interventions
SufentanilDrug
The postoperative PCA analgesia pump configuration plan is 1.5 μg/kg sufentanil diluted with saline to 100 ml. The specific parameters are a loading dose: 0.1 μg/kg sufentanil diluted with saline to 3 ml, administered 20-30 minutes before the end of surgery. Background infusion rate: 1.5 ml/h, PCA dose: 1 ml, lockout time: 10 minutes.
OiceridineDrug
The postoperative PCA analgesic pump regimen is 0.5 mg/kg of oliceridine diluted with saline to 100 ml. The specific parameters are a loading dose: 0.03 mg/kg of Oxycodone diluted with saline to 3 ml, administered 20-30 minutes before the end of surgery. Background infusion rate: 1.5 ml/h, PCA dose: 1 ml, lockout interval: 10 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients reaching the GI-3 composite endpoint within postoperative 24 hoursTime frame: postoperative 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
the First Affiliated Hospital of Air Force Military Medical University
Xi'an, Shaanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.